Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Montelukast and psychiatr… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Montelukast and psychiatric disorders in children.

Artikel i vetenskaplig tidskrift
Författare Susanna Maria Wallerstedt
Gertrud Brunlöf
Anders Sundström
Anna L Eriksson
Publicerad i Pharmacoepidemiology and drug safety
Volym 18
Nummer/häfte 9
Sidor 858-64
ISSN 1099-1557
Publiceringsår 2009
Publicerad vid Institutionen för medicin, avdelningen för klinisk prövning och entreprenörskap
Sidor 858-64
Språk en
Länkar dx.doi.org/10.1002/pds.1794
Ämnesord Acetates, adverse effects, Adolescent, Adverse Drug Reaction Reporting Systems, Anti-Asthmatic Agents, adverse effects, Child, Child, Preschool, Female, Humans, Infant, Male, Mental Disorders, chemically induced, Quinolines, adverse effects, Sweden
Ämneskategorier Klinisk farmakologi

Sammanfattning

PURPOSE: A signal has been raised concerning montelukast and adverse drug reactions (ADRs) in children. The purpose of the present study was to evaluate psychiatric ADRs during treatment with montelukast in children. METHODS: We analyzed all reports of psychiatric disorders during treatment with montelukast in children (<18 years) in the Swedish ADR database SWEDIS (1998-2007). The Bayesian Confidence Propagation Neural Network (BCPNN) method was used to screen for disproportional reporting rates of these reactions. An information component (IC) with a positive 95% lower confidence limit indicates a statistically significant disproportionality between the expected and the reported rate for a drug and an ADR. RESULTS: A total of 48 reports of psychiatric disorders in children during treatment with montelukast were found in SWEDIS. Reports appeared every year after registration. Psychiatric disorders reported more than once included nightmares (n = 15), unspecified anxiety (n = 11), aggressiveness (n = 11), sleep disorders (n = 10), insomnia (n = 3), irritability (n = 3), hallucination (n = 3), hyperactivity (n = 3), and personality disorder (n = 2). In 23 reports (48%), the child experiencing psychiatric ADRs was < or = 3 years old. Time from exposure to ADR was indicated in 35 reports. In 28 of these (80%), the time from exposure to ADR was less than 1 week. A statistical signal for psychiatric disorders appeared in the fourth quarter of 1998 (three reports, IC-value: 2.34, 95% lower confidence limit: 0.62). CONCLUSIONS: Psychiatric ADRs can occur during montelukast treatment in children, indicating that attention to this is essential. Further studies are needed to establish the magnitude of the problem.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://gu.se/forskning/publikation/?publicationId=110744
Utskriftsdatum: 2020-05-29